Is BPC-157 Legal in Minnesota? Federal Status, Prescription Rules, and How to Get It

What is BPC-157's federal status?

BPC-157 is a synthetic peptide of 15 amino acids, molecular weight about 1419.5 g/mol, described as a fragment of a protein first isolated from human gastric juice [1]. It is not an FDA-approved drug: no approved drug contains it, there is no US Pharmacopeia or National Formulary monograph for it, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

Where does it sit in FDA's compounding rules?

From September 2023 until April 22, 2026, BPC-157 was in FDA's category 2 table of bulk substances that may present significant safety risks when compounded [5]. It now sits in a separate 'nominated but withdrawn' table because the groups that nominated it withdrew, and the same page still carries FDA's concerns, including immunogenicity risk for certain routes and insufficient information to know whether the drug would harm humans [5]. Removal was not a finding of safety [5].

On FDA's list of nominated bulk substances for state-licensed pharmacies (updated May 14, 2026), BPC-157 is in none of the three categories, so category 1 does not cover it [4]. It is also absent from FDA's list for outsourcing facilities (updated March 21, 2025) [7].

FDA's own reviewers proposed in July 2026 that BPC-157 not be added to FDA's pharmacy bulks list, citing limited chemical characterization, little safety and immunogenicity information, and insufficient evidence for ulcerative colitis [1]. FDA's Pharmacy Compounding Advisory Committee voted in favor of adding it on July 23, 2026, but advisory committees make non-binding recommendations, and BPC-157 is not on the list [10].

What did HHS say in October 2026?

A notice filed October 28, 2026 announced a draft enforcement-discretion policy for six peptides including BPC-157, scheduled for Federal Register publication on October 30, 2026, with comments open two weeks [2]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide if the conditions are met [2]. For BPC-157 the conditions include BPC-157 acetate only, in subcutaneous, intramuscular, oral or topical forms, as a single active ingredient, with a patient-specific prescription, a bulk substance from an FDA-registered manufacturer with a certificate of analysis, required labeling, and reporting of serious adverse events to FDA MedWatch. Oral forms need documentation of adequate bioavailability [8][2]. The notice states the policy does not establish rights for any person and is not binding on HHS or the public, and compounded drugs are not FDA-approved [2].

What does Minnesota law add?

Minnesota Chapter 151 is the Pharmacy Practice and Wholesale Distribution Act. Its table of sections includes 151.15, "Compounding drugs unlawful under certain conditions," and 151.253, "Compounding" [3]. The federal position above does not by itself settle how Minnesota authorities would treat a BPC-157 prescription [1][4][2][3].

Is BPC-157 prohibited for athletes?

WADA names BPC-157 in S0, non-approved substances, prohibited at all times in and out of competition, in the 2026 List in force since January 1, 2026 and again in the 2027 List [6][9].